Published in Cancer on January 10, 2011
Accurate three-dimensional virtual reconstruction of surgical field using calibrated trajectories of an image-guided medical robot. J Med Imaging (Bellingham) (2014) 1.58
Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol (2014) 0.99
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer (2013) 0.99
Hyperactivation of Akt/mTOR and deficiency in tuberin increased the oxidative DNA damage in kidney cancer patients with diabetes. Oncotarget (2014) 0.92
Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol (2016) 0.91
Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol (2013) 0.90
Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome. World J Urol (2016) 0.87
Bilateral synchronous adrenal metastases of renal cell carcinoma: A case report and review of the literature. Oncol Lett (2015) 0.86
Potentially curable recurrent disease after surgically managed non-metastatic renal cell carcinoma in low-, intermediate- and high-risk patients. World J Urol (2016) 0.86
A unique presentation of a renal clear cell carcinoma with atypical metastases. Int J Surg Case Rep (2015) 0.85
Twelve-year survival after multiple recurrences and repeated metastasectomies for renal cell carcinoma. World J Surg Oncol (2011) 0.85
The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma. World J Urol (2014) 0.85
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival. Medicine (Baltimore) (2015) 0.85
Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World J Urol (2016) 0.85
The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. World J Urol (2013) 0.84
8-year survival in a patient with several recurrences of renal cell carcinoma after radical nephrectomy. Cent European J Urol (2012) 0.82
Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLoS One (2013) 0.81
The epigenetic landscape of renal cancer. Nat Rev Nephrol (2016) 0.81
The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Biomed Res Int (2015) 0.81
Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol (2015) 0.78
Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. Eur Urol (2016) 0.78
Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. J Surg Oncol (2016) 0.78
Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma? World J Nephrol (2015) 0.77
Cryosurgery/cryoablation in musculoskeletal neoplasms: history and state of the art. Curr Rev Musculoskelet Med (2015) 0.77
Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma. EJC Suppl (2013) 0.76
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J (2011) 0.76
Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol (2011) 0.76
The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Indian J Urol (2014) 0.76
Surgery of non-spinal skeletal metastases in renal cell carcinoma. Acta Orthop (2016) 0.75
Metachronous adrenal metastasis from operated contralateral renal cell carcinoma with adrenalectomy and iatrogenic Addison's disease. Can Urol Assoc J (2014) 0.75
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer (2016) 0.75
A Synchronous Pancreatic Metastasis from Renal Clear Cell Carcinoma, with Unusual CT Characteristics, Completely Regressed after Therapy with Sunitinib. Case Rep Med (2014) 0.75
Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? Clin Transl Imaging (2016) 0.75
Treatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010). J Cancer (2016) 0.75
Microarray profile of human kidney from diabetes, renal cell carcinoma and renal cell carcinoma with diabetes. Genes Cancer (2015) 0.75
A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma. J Clin Med Res (2017) 0.75
The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy. BMC Surg (2016) 0.75
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement. J Multidiscip Healthc (2015) 0.75
The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol (2016) 0.75
Renal cell carcinoma with metachronous metastasis to the contralateral adrenal gland and urinary bladder: A case report. Oncol Lett (2015) 0.75
Cytological Assessments and Transcriptome Profiling Demonstrate that Evodiamine Inhibits Growth and Induces Apoptosis in a Renal Carcinoma Cell Line. Sci Rep (2017) 0.75
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Front Oncol (2017) 0.75
Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol (2016) 0.75
Severe blood loss anaemia and recurrent intussusceptions as first presentation of bowel metastatic renal cell carcinoma: A case report and review of the literature. Mol Clin Oncol (2017) 0.75
miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis. Oncol Lett (2017) 0.75
Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Int J Radiat Oncol Biol Phys (2017) 0.75
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med (2002) 4.18
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol (2004) 3.92
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol (2013) 3.11
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. J Urol (2006) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer (2014) 2.77
Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol (2012) 2.73
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors. Eur Urol (2012) 2.52
Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol (2010) 2.45
Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res (2005) 2.42
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol (2008) 2.40
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36
Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. Radiology (2012) 2.35
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet (2004) 2.31
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol (2011) 2.22
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol (2007) 2.12
Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol (2005) 2.10
Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol (2004) 2.08
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol (2009) 2.05
Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol (2010) 2.05
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol (2005) 2.01
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer (2009) 2.00
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int (2004) 2.00
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int (2005) 2.00
The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol (2013) 1.99